Cargando…
Sphingosine 1-Phosphate Receptor 2 Induces Otoprotective Responses to Cisplatin Treatment
Ototoxicity is a major adverse effect of platinum-based chemotherapeutics and currently, there remains a lack of United States Food and Drug Administration-approved therapies to prevent or treat this problem. In our study, we examined the role of the sphingosine 1-phosphate receptor 2 (S1P(2)) in at...
Autores principales: | Wang, Wei, Shanmugam, Muthu K., Xiang, Ping, Yam, Ting Yu Amelia, Kumar, Vineet, Chew, Wee Siong, Chang, Jing Kai, Ali, Muhammad Zulfaqar Bin, Reolo, Marie J. Y., Peh, Yee Xin, Abdul Karim, Siti Nasuha Binte, Tan, Andrew Y.Y., Sanda, Takaomi, Sethi, Gautam, Herr, Deron R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016659/ https://www.ncbi.nlm.nih.gov/pubmed/31952197 http://dx.doi.org/10.3390/cancers12010211 |
Ejemplares similares
-
Sphingosine 1-phosphate receptor 2 (S1P(2)) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy
por: Herr, Deron R., et al.
Publicado: (2016) -
The Use of Nanoparticles in Otoprotection
por: Barbara, Maurizio, et al.
Publicado: (2022) -
Persistence of the otoprotective effect. How long does otoprotection against amikacin lasts?
por: de Oliveira, Andreia Ardevino, et al.
Publicado: (2015) -
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
por: Sheth, Sandeep, et al.
Publicado: (2017) -
Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer’s disease and vascular cognitive impairment
por: Chua, Xin Ying, et al.
Publicado: (2020)